DexCom Inc (DXCM)

Currency in USD
82.89
+0.23(+0.28%)
Real-time Data·
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
82.4783.67
52 wk Range
54.1187.85
Key Statistics
Prev. Close
82.66
Open
82.91
Day's Range
82.47-83.67
52 wk Range
54.11-87.85
Volume
1.5M
Average Vol. (3m)
5.78M
1-Year Change
8.5079%
Book Value / Share
6.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
93.44
Upside
+12.73%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

DexCom Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

25 Buy
3 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 93.44
(+12.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy95.00+14.60%-MaintainAug 03, 2026
Canaccord
Buy90.00+8.56%82.00MaintainAug 03, 2026
TD Cowen
Buy95.00+14.60%-MaintainJul 31, 2026
JPMorgan
Hold82.00-1.09%65.00MaintainJul 31, 2026
Wells Fargo
Buy90.00+8.56%85.00MaintainJul 31, 2026

DexCom Inc SWOT Analysis


Quality vs. Margins
Discover how Dexcom's quality enhancement initiatives create near-term profitability pressures while potentially building long-term competitive advantages
Competitive Battlefield
Intensifying rivalry in Type 1 and intensive Type 2 diabetes markets threatens market share as new entrants and established players introduce alternative solutions
Analyst Targets
Price targets range from $71 to $80, reflecting mixed analyst sentiment on the company's ability to navigate competitive pressures and margin challenges
Q4 Performance Shines
Dexcom exceeded Q4 sales and earnings expectations, demonstrating operational strength in diabetes management technology despite market uncertainties
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q2/2026

  • Dexcom Q2 profit hit $0.70/share on $1.31B revenue, beating estimates of $0.61/share and $1.29B; shares surged 8.64% after-hours to $80.98.
  • Revenue rose 13% YoY with U.S. sales up 11% to $933M and international up 19% to $375M; gross margin expanded to 64.1% from 60.1% prior year.
  • Company raised FY2026 revenue guidance to $5.18B-$5.25B (11-13% growth) and lifted margin targets to 64% gross, 23.5-24% operating, 31.5-32% EBITDA.
  • G7 15-day system on track to convert nearly half of U.S. customers by year-end; CONNECT trial showed 1.6% A1C improvement supporting broader adoption.
  • Free cash flow exceeded $600M in H1 2026, more than double prior year; company faces $15M FX headwinds and Ireland factory startup costs in H2.
Last Updated: 07/30/2026, 05:47 PM
Read Full Transcript
DexCom investor slides for Q2/2026
Dexcom Q2 2026 slides
Last Update: Jul 30, 2026
See full investor slides

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
0.70 / 0.61
Revenue / Forecast
1.31B / 1.29B
EPS Revisions
Last 90 days

DXCM Income Statement

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
31.4x20.1x−0.4x
PEG Ratio
0.42−0.730.00
Price / Book
12.0x2.8x2.6x
Price / LTM Sales
6.3x2.8x3.0x
Upside (Analyst Target)
12.5%26.9%51.8%
Fair Value Upside
Unlock−9.4%7.2%Unlock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
216.67M56.15%17.91B
Other Institutional Investors
167.16M43.32%13.82B
Public Companies & Retail Investors
2.03M0.53%168.06M
Total
385.87M100.00%31.9B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.10%38,964,3713,220,795
Vanguard Capital Management, LLC6.48%25,020,9612,068,233

People Also Watch

867.16
LITE
+4.95%
109.79
SPCX
+1.40%
263.30
CEG
-0.69%
898.01
MU
+0.54%
219.19
NVDA
-0.01%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 82.89 USD.

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 31.31B USD.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 2.54.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on Oct 22, 2026.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 11050 employees.

What is the current trading status of DexCom (DXCM)?

As of Aug 06, 2026, DexCom (DXCM) is trading at a price of 82.89 USD, with a previous close of 82.66 USD. The stock has fluctuated within a day range of 82.47 USD to 83.67 USD, while its 52-week range spans from 54.11 USD to 87.85 USD.

What Is DexCom (DXCM) Price Target According to Analysts?

The average 12-month price target for DexCom is 93.44 USD, with a high estimate of 115 USD and a low estimate of 79 USD. 25 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.73% Upside potential.

What Is the DXCM Premarket Price?

DXCM's last pre-market stock price is 82.80 USD. The pre-market share volume is 2,160.00, and the stock has decreased by 0.14, or 0.17%.

What Is the DXCM After Hours Price?

DXCM's last after hours stock price is 83.30 USD, the stock has decreased by 0.64, or 0.77%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.